Jump to Main Content
Development and validation of analytical methodologies for the quantification of PCK3145 and PEG-PCK3145 in mice
- Danika, Charikleia, El Mubarak, Mohamed A., Leontari, Iliana, Sivolapenko, Gregory B.
- Analytical biochemistry 2019 v.564-565 pp. 72-79
- bioavailability, blood, enzyme-linked immunosorbent assay, half life, mice, monitoring, pharmacokinetics, prostatic neoplasms, proteolysis, quantitative analysis, synthetic peptides, tandem mass spectrometry, ultra-performance liquid chromatography
- PCK3145 is an anti-metastatic synthetic peptide against prostate cancer. The objective of the study is to develop and validate novel and sensitive methods for the determination of PCK3145 and Pegylated PCK3145 in mouse plasma. An LC–MS/MS method was developed and validated for the determination of PCK3145 giving high sensitivity and linearity in the range of 0.125–4.0 μg/mL. PCK3145 characterised by short half-life, therefore, it was conjugated with the poly ethylene glycol (PEG). However, LC-MS/MS has been more difficult to apply for the quantitative analysis of PEGylated peptides due to the large size. A UHPLC-UV method was developed and validated for the determination of PEG-PCK3145, with linearity of 0.05–2.0 mg/mL. In order to further improve the sensitivity for the detection of PEG-PCK3145, an indirect ELISA method was used. It was found that this method was capable of detecting PCK3145 through the quantification of PEG with excellent sensitivity found at 0.132 ng/mL. The in vitro proteolytic stability of PCK3145 and PEG-PCK3145 in mouse plasma and whole blood was studied by LC-MS/MS and UHPLC, respectively. The LC–MS/MS and ELISA methods can be applied for monitoring levels of PCK3145 in mouse plasma for in vivo pharmacokinetic and bioavailability animal studies.